Welcome David Guyer, MD, to our Board of Directors! With over 30 years of drug development experience, he brings invaluable expertise as we continue advancing our Partial Epigenetic Reprogramming Platform toward the clinic in 2026. Read more:
40,535 görüntüleme
Pleased to announce the first patient has been dosed in our Phase 1 clinical trial, evaluating our lead candidate for optic neuropathies. This marks a key milestone as our epigenetic restoration therapy enters the clinic for glaucoma & NAION. Read more:
11,683 görüntüleme
Proud to be featured in TIME TIME100 Companies: New Frontiers, recognizing our work to reverse age-related diseases by targeting the biology of aging. We’re honored by this recognition & remain committed to advancing transformative therapies. Read more:
13,607 görüntüleme
We’ve closed a fully-subscribed $80 million financing to support our ongoing clinical trial in optic neuropathies and advancement of our Partial Epigenetic Reprogramming platform across multiple indications. Read more:
14,044 görüntüleme
Q1 kicked off with strong momentum as our leadership team engaged across key industry forums, sharing perspectives on our Partial Epigenetic Reprogramming platform aimed at reversing age-related disease. Stay up to date on our progress:
12,596 görüntüleme
We’re pleased to announce we’ve received FDA IND clearance for our cellular rejuvenation therapy using partial reprogramming for optic neuropathies, including glaucoma and NAION. Read more in our press release:
